semaglutide injection compound pharmacy Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market Take control of your health

mainly for Type 2 diabetes and obesity

To view or add a comment, sign in While Lilly and Novo dominate today's $50B+ obesity market, Pfizer is preparing a killer portfolio to steal the spotlight in 2030s

Although the steric bulk of the (CH 2 )3 side chain might diminish activity relative to the natural GLP-1R agonists, these replacements should test the hypothesis that GLP-1R agonist activity is higher for ligands that can access non-helical conformations near the N-terminus, compared to those that cannot

This is the only delivery method that has been studied in clinical trials to date

Liraglutide and cardiovascular outcomes in type 2 diabetes

What is the fastest way to reduce pimple redness